Vermont bill proposes a Psychedelic Therapy Advisory Board to review psychedelic therapy research and ibogaine clinical trials.

The Vermont bill establishes a Psychedelic Therapy Advisory Board to review research on psychedelic therapy's cost-benefit profile and its impact on mental health and substance use disorders. The Board will also propose recommendations for establishing a state program to permit health care providers to administer psychedelics in a therapeutic setting. Additionally, the bill mandates the Department of Health to contract with a Vermont entity for ibogaine clinical drug development trials, focusing on opioid use disorder, co-occurring substance use disorder, and other mental health or.

Vermont bill proposes a Psychedelic Therapy Advisory Board to review psychedelic therapy research and ibogaine clinical trials.

The Vermont bill establishes a Psychedelic Therapy Advisory Board to review research on psychedelic therapy's cost-benefit profile and its impact on mental health and substance use disorders. The Board will also propose recommendations for establishing a state program to permit health care providers to administer psychedelics in a therapeutic setting. Additionally, the bill mandates the Department of Health to contract with a Vermont entity for ibogaine clinical drug development trials, focusing on opioid use disorder, co-occurring substance use disorder, and other mental health or.